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Summary
This report describes a murine amniotic fluid (MAF) immunosuppressive factor that has properties
similar to transforming growth factor0 (TGF-R). The MAP factor exhibits TGF-0-like activity
in stimulating soft agar colony formation by AKR-2B cells and inhibiting thymidine uptake
by Mv1Lu cells. We demonstrate that both the immunosuppressive and TGF-#-like activities
ofthe MAP factor are completelyneutralized by anti TGF-02-specific antibodies and not by anti-
TGF-/31-specific antisera. The immunosuppressive factor in MAP is novel in that it appears to
be identical or very closely related to TGF-02 and is active in its native state. This active and
antiTGF-,32-neutralizable factor chromatography at -70 kD on Sephadex at neutral pH and
appears to be able to complex with ci-fetoprotein in native amniotic fluid. Chromatography of
native MAP under acidic conditions demonstrates a lower molecular mass protein that chromato-
graphs on BioGel in the same position as the mature 25-kD TGF-0. This protein has thebiological
properties of TGF-O and is immunosuppressive. Both of these activities are neutralizable with
antiTGF-/32 but not with anti TGF-/31 or other antisera. By Northern analysis, we find high
levels of TGF-f2 mRNA (with little or no TGF-fl) in the pregnant uterus that peak around
day 15 of gestation and then fall rapidly by day 19 as birth approaches. The TGF-X32-like factor
could possibly play a role in maternal immunity, in the retention of the fetal allograft, as well
as in regulating fetal and neonatal immunological competence.
S
everal factors have been implicated in the maternal toler-
ance to the semiallogeneic fetus and the immunological
deficiencies described in pregnancy, as well as the fetus and
neonate (reviewed in references 1 and 2). This includes evi-
dence that deficiencies in MHC class I and class II antigen
expression on fetal and maternal tissues may play a role in
maternal tolerance. Different T cell subsets and especiallysup-
pressor cells have also been implicated in pregnancy-related
immune suppression and in the immunotrophic promotion
offetaldevelopment (1, 2). Neonatal natural suppressor cells
inhibit immune responses and may be involved in tolerance
induction in the fetal and neonatal periods (3). In addition,
soluble suppressive factors influencing immune development
in the fetus and newborn, and immunity during pregnancy,
havebeen described (1), and these may mediate and/or com-
plement the cellular suppressors.
We have previously reported (reviewed in references 4 and
5) the immunosuppressive effects of murine amniotic fluid
(MAF)' both in vitro and in vivo, and have suggested that
the MAP suppressive factor could potentially be important
in regulating immunity during pregnancy and in the new-
born period. MAP has been found to inhibit splenic anti-
body responses to SR.BC and the primary and secondary re-
sponses to other T-dependent antigens, as well as the MLR
and T cell mitogen stimulation. The in vivo administration
of MAP to newborn mice prolongs neonatal immunological
immaturity (6), and we have demonstrated that MAP ad-
ministered to mice intraperitoneally suppresses donor skin
graft rejection across the H-Y histocompatibility antigen barrier
(7). Although the suppressive activity in MAP has been found
to co-purify with ci-fetoprotein (AFP), the relationship of
the immunosuppressive activity in MAP to AFP has not been
clearly established (4, 5, 8). Variations in the suppressive
'Abbreviations used in this paper . AFP, a-fetoprotein; MAF, murine amni-
otic fluid; NMS, normal mouse serum.
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attributed to the binding of small molecules, the presence
of Cue-' chelated at a critical histidine (4, 5), and/or a chem-
ical isoform of APP that is suppressive (9).
Transforming growth factor0 (TGF-S) is a family of struc-
turally and functionally related molecules (reviewed in refer-
ences 10 and 11) that have been shown to be present in the
mouse embryo (12, 13) and are differentially regulated in var-
ious tissues during development (13, 14). Other more dis-
tantly related developmental regulators that are members of
the TGF-0 superfamily include: the Xewpw Vg-1 geneproduct
and its mammalian homologue Vgr-1, the decapentaplegic
(dpp) proteinofDrosophila, the bone morphogenetic proteins
(BMP-2a, 2b, 3) Mullerian, inhibiting substance and the in-
hibins/activins (see review in reference 10). TGF-0 has been
shown to inhibit a variety of immune responses (15-20). We
have reported in preliminary studies (21, 22) that TGF-0 shares
some of the characteristics of the amniotic fluid immunosup-
pressive factor. We also noted that both the amniotic fluid
immunosuppressive factor and TGF-0 modulated MHC class
II gene expression induced by certain lymphokines and
cytokines (21, 23). In this report, we demonstrate that the
MAF suppressive factor is closely related to or identical with
TGF-Q2, and that it can complex with AFP in native am-
niotic fluid. Extremely high levels of TGF-02 mRNA are
found in uterine tissue after day 9.5 of pregnancy reaching
a maximum by day 15.5, after which there is a rapid fall by
day 19 as birth approaches. The TGF-132-like factor may play
an important role in the maintenance of pregnancy and in
the regulation of immunity in the fetus and neonate.
Materials and Methods
Mice. The Swiss, DBA/2Ha, and C3Hf/He mice were ob-
tained from the West Seneca Laboratories (West Seneca, NY) of
the Roswell Park Cancer Institute (RPCI), and the CBA micewere
obtained from Cumberland Farms (Clinton, TN). Micewere cared
for in the RPCI Animal Care Facility. The day of detection of vag-
inal plugs was considered day 0.5 of gestation.
MAFPreparation.
￿
Fluid was removed from the fetal amniotic
sacs of 15-d pregnant Swiss mice, stored at 4°C, pooled, and the
absorbance at 280 nm (Ano) was adjusted to 2.0 U/ml with PBS.
The MAF was filter sterilized (0.2 pm), aliquoted, and stored at
-70°C. Heat-treated MAF was prepared by heating MAF in a
boiling water bath at >95°C for 7 min followed by centrifugation
and removal of the supernatant. PBS or pooled Swiss normal mouse
serum (NMS), diluted to 2.0 Also U/ml, were used as controls.
All MAF preparations were tested negative for endotoxin by the
Limulus Amebocyte Lysate gel clot method (ACCU-Gel; Whit-
taker MA Bioproducts, Walkersville, MD).
Antigen-inducedTCell Proliferation Assay.
￿
Female CBA mice at
6-8 wk of age wereimmunizedat the base ofthe tail and the footpad
with 100 and .25 Ecg, respectively, of OVA in H37/Ra complete
adjuvant (Difco Laboratories, Detroit, MI). After 7d, the inguinal,
para-aortic, and popliteal lymph nodes were removed, and a single
cell suspension was prepared and cultured in 96-well flat-bottomed
tissue culture plates (Corning Glass Works, Corning, NY) at 4
x 105 cells/well in 200 F1 of RPMI 1640with L-glutamine (Gibco
Laboratories, Grand Island, NY), penicillin, streptomycin, 5 x
10-5 M 2-ME, and 1% fresh NMS. Triplicates were set up with
1392
and without 0.25 mg/ml OVA, and MAF, control NMS, or PBS
were added at varying concentrations (5-10% [vol/vol] being stan-
dard). Porcine platelet-purified TGF-01 and (32 (R & D Systems,
Minneapolis, MN) were titered for activity and used at 2 ng/ml
or less. Rabbit polyclonal neutralizing anti TGF-(3 and antiTGF-
02 (R & DSystems) were titered and used at 75-150 and 40 Wg/ml
or less, respectively. Turkey antiTGF-#l and antiTGF-a2 obtained
from Drs. Linda Dart and Michael Spom (24, 25) were used at
1:5,000 to 1:100 dilutions with media. Culture plates wereincubated
for 72 h at 37°C in 5% C02, then pulsed for 18 h with 1 ACY
well of [3H]TdR (2 Ci/mmol; New England Nuclear, Boston,
MA), harvested, and counted in a scintillation counter. All experi-
ments were repeated at least three times.
TGF-0Activity Assays.
￿
TGF-/3-like activity in MAF was assayed
as follows. Soft agar colony formation ofAKR2B cells cultured
in 0.4% agarose in 6-well plates (Coming Glass Works) at 7,500
cells/well in McCoy 5A (Gibco Laboratories) with 5% FCS (Hy-
Clone Laboratories, Logan, UT) was assayed as described (12, 26,
27) in response to the indicated concentrations ofTGF-0 or MAF
(or PBS or NMS controls). Dishes were incubated at 37°C in 5%
C02 for 10 d, and colonies were then counted (Gaertner Scientific
Co., Chicago, IL). Assay of the growth inhibitionof Mv1Lu mink
lung epithelial cells (CCL64; American Type Culture Collection,
Rockville, MD) by TGF-0 (27, 28) was modified as follows.
Subconfluent cultures were trypsinized, washed, and seeded at 3 x
10' cells/well in 24-well culture plates (Corning Glass Works) in
1 ml ofDMEM (Gibco Laboratories) with 10% supplemented calf
serum (Hyclone Laboratories) and incubated at 37°C in 5% C02
for 72 h. Media was then changed to DMEMwith 5% FCS, and
24 hlater, TGF-A, MAF, heat-treated MAF, PBS, orNMS, and/or
the various anti TGF-(3 antibodiesdescribed above were added, and
the plates were incubated for an additional 22 h. Media was then
aspirated, and 1 uCi/well of [3H]TdR (2 Ci/mmol; New England
Nuclear) was added in 0.5 ml of MEM with 5% calf serum and
incubated for 2 h. Cells were fixed with 10% ice-cold TCA, dis-
solved in 0.25 N NaOH, and counted in a scintillation counter.
IIA ThymocyteProliferation Assay.
￿
The IIA-dependent thymo-
cyte proliferation assaywas carried out essentially as described (16).
Thymocytes were prepared from C3Hf/He mice and cultured in
96-well tissue culture plates (Corning Glass Works) at 1.5 x 106
cells/wellin RPMI 1640 with 1% fresh NMS. PHA was used at
1 Fzg/ml, and I1A (Genzyme Corp., Boston, MA) was added at
10 U/ml. TGF-f3 was added at 2 ng/ml and MAP at 10% (vol/vol).
Plates were incubated for 72 h and then pulsed for 18 h with 1
IACi/well of [3H]TdR, harvested, and counted as described above.
Bone Marrow SoftAgar Colony Assay.
￿
Bone marrow was flushed
from the femurs and tibias of 8-10-wk-old female DBA/2Ha mice.
The cells were washed and cultured at 105 cells/ml/well in 24-well
culture plates in ot-MEM (Gibco Laboratories), 10% FCS, peni-
cillin, streptomycin, and 0.3% bactoagar (Difco laboratories) in
the presence or absence of rhuCSF-1 (Genzyme Corp.) at 100
CFU/ml (1 CFU is the amount required to produce one colony
of >50 cells from 7.5 x 10° murine bone marrow cells in soft agar
after 7 d), or with amniotic fluid, heat-treated amniotic fluid, or
NMS at 10% (vol/vol). The plates were allowed to gel at room
temperature and were then incubated at 37°C in 5% C02. Colo-
nies of >50 cells were counted at 7 and 14 d.
Size Exclusion Gel Chromatography.
￿
MAF was concentrated on
an ultrafiltration cell (model 52; Amicon Corp., Danvers, MA) with
a Diaflo YM5, 5000 MWCO membrane, and dialyzed exhaustively
against PBS. The concentrated MAF was applied to a column of
Sephadex G-150 (Pharmacia Fine Chemicals, Piscataway, NJ)
equilibrated with PBS at pH 7.1, and fractions were collected,
Amniotic TGF-02-like Immunosuppressor and Uterine TGF-02 mRNApooled, and tested for suppressive activity in the antigen-induced
Tcellproliferation andmink cell inhibition assays (described above).
Acid (pH 2.3) chromatography was performed on BioGel 1`100
(100-200 mesh; Bio-RadLaboratories,Richmond, CA) equilibrated
with 1 M acetic acid at pH 2.3. MAP was first dialyzed against
1 Macetic acid, then applied to thecolumn, andthecollectedfrac-
tions were neutralized andtested forsuppressive activity. The im-
munosuppressiveactivity (U/Wg) of thechromatographic fractions
were expressedas unitsofthebiologic response causing 50% inhi-
bition of maximal stimulation in the T cell assay per microgram
of protein in the fraction. Human platelet-purified TGF-ail was
prepared as previously described (29). Controlled pore glassbeads
(CPG Inc., Fairfield, NJ) were of 343-A mean pore diameter and
120/200particle size. Rabbit anti-mouse AFPwasprepared against
AFP from ascites fluid(ICN Immunobiologicals, Lisle, IL) andwas
used without furtherpurification. Goat anti-NMS (AccurateChem-
ical &Scientific Corp., Westbury, NY) andanti-mouse IgG(ICN
Immunobiologicals) were also used (as controls) without further
purification.
RNA Isolation.
￿
Maternal andfetaltissues were removed from
Swissmice at days 9.5, 12.5, 15.5, and 19 of gestationwith careful
dissection (30, 31), and total RNA was isolated by the guanidine
thioryanate-CsCl method (32). Briefly, tissues were rapidly dis-
rupted in 4 M guanidinium thiocyanate, 25 mM sodium citrate,
pH 7.0, 0.1 M 2-ME, and 0.5% sodium N-laurylsarcosine using
a Tissumizer homogenizer (Tekman Industries, Cincinnati, OH).
The homogenates were carefully layered over 5.7 M cesium chlo-
ride and centrifuged in a SW50.1 rotor (Beckman Instruments,
Inc., Fullerton, CA)at 36,000 rpmfor 16-18hat 20°C. The RNA
pellet wasdissolvedin 7.5 M guanidinehydrochloride, 25 mM so-
dium citrate, pH 7.0, and 10 mM 2-ME. The RNA was precipi-
tatedby adding 0.025 vol of 1 Macetic acid and0.5 volof absolute
ethanol, pelleted by centrifugation, andresuspended in water. RNA
was reprecipitated by adding 2 M potassium acetate, pH 5, (0.1
vol) andethanol (2.5 vol). The RNApellet was dissolved in water
andquantified spectrophotometrically. ThePC-3 adenocarcinoma
cell line (American Type CultureCollection) wasused as acontrol
and grown in DMEM with 10% FCS. PC-3 RNA was prepared
identically to the tissue RNAs.
Northern Analysis.
￿
TotalRNA (30 Ftg/lane)wasdenatured by
incubation at 50°C for 1 h in glyoxal-DMSO andsubjectedto 1%
agarose gelelectrophoresis. Afterelectrophoresis, the gelwasdried
in a gel slab dryer (model 224; Bio-Rad Laboratories) with heat
on for 1.5 h, andhybridization wasperformeddirectly on thedried
gel (33). Both prehybridization andhybridizations were performed
in 5x SSC, 25 mM sodium phosphate(pH 7),0.1%SDS, 5x Den-
hardt's solution (0.1% Ficoll, 0.1%polyvinylpyrrolidone, and0.1%
BSA), and 100 Wg/ml sonicated, denatured salmon sperm DNA,
at 65°C overnight. DNA fragments were 'z1` labeled by the
random primer technique (34) to a sp act of 109 cpm/1`.g DNA.
Heat-denatured 32P-labeled probes (1-2 x 106 cpm/ml hybridiza-
tion solution) were added. Afterhybridization, gels were washed
for 30 min at room temperature with 2x SSC, 0.05% Sarkosyl,
and 0.02% sodium pyrophosphate; for 2 h at 50°C with 0.2x
SSC, 0.05% Sarkosyl, and0.01% sodium pyrophosphate; andfor
30 min at 55°C with 0.2x SSC, 0.05% Sarkosyl, and 0.01% so-
dium pyrophosphate. The resulting gels were blot dried and au-
toradiographed at -70°Con KodakXAR-5 film,utilizingDupont
Cronex intensifying screens. RNA ladders (Bethesda Research
Laboratories, Gaithersburg, MD) processedidentically to thetissue
RNAs were used as molecular weight standards.
ProbesforHybridization.
￿
TheprobeforTGF-02 used in this study
is aTGF-02-specific 929-bp EcoRl-HindIII fragment generatedby
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restriction digestion of plasmid pPC-21 (2.3 kb), a cDNA clone
of human TGF-S2 (35). The929-bp EcoRI-HindIIlfragment con-
tains 179-bp of 5' noncodingas well as 750-bp ofprecursorcoding
region. This eliminates the 3' terminal mature region of thecDNA,
whichis theregion of highest sequence conservation in theTGF-0
family. The probe specific for TGF-S1 is a 1,600-bp EcoRI frag-
ment obtained from restriction digestionof plasmidplGF-S (1)-2,
a cDNA clone of simian TGF-01 (36), which co"s the entire
TGF-01 precursor coding region as well as the3'terminal mature
region. Both pPC-21 and pTGF-i8 (1)-2 were kindly provided by
Dr. A. F.Purchio.PlasmidpIr7,acDNA cloneofmouseribosomal
protein L7 (37), was agift from Dr. R. P. Perry. pI,7 wascleaved
with EcoRI and HindIII to generate a 540-bp fragment and was
used as an internal hybridization intensity control.
Results
Immunosuppriessive Activity ofMAFand7GR0.
￿
MAF sup-
presses the in vitro antigen-induced proliferation of ovalbumin
sensitized lymph node T cells in a dose-dependent manner
(Fig. 1). Thymidine incorporation is significantly inhibited
by 1% MAF, while 5% MAP inhibits by >90%, and 10%
MATby 97% with no effect on cell viability . Syngeneicadult
normal mouseserum (atthesame protein concentration) has
no effect. Both TGF-/31 and TGF-02 at 2 ng/ml suppress
T cell proliferation to approximately the same extent as 5%
MAF. Concentrations of TGF-02 as low as 0.5 ng/ml
significantly suppress this response (TGF-01 exhibitedabout
half the suppressive potency of TGF-)(32; data not shown).
Suboptimal concentrations of MAP and TGF-a2 exhibit ad-
ditive inhibition to the maximum seen with optimal con-
centrations ofeither. Similar suppression by MAP, andTGF-
a1 and TGF-(32, is observed in the MLR, T cell mitogen
stimulation (data not shown), and the IM-dependent stim-
ulation of murine thymocyte proliferation (Fig. 2).
Characterization ofthe 'IGRO-like Activities ofMAR MAF.
￿
Bio-
logical activities classically attributed to TGF-0 are present
in MAR SinceTGF-0 stimulates AKR2B mouseembryonic
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￿
Dose response ofamniotic fluidandTGF-fl-induced suppres-
sion of antigen-specific T cell proliferation. OVAprimed mouseLN cells
were cultured, in thepresence or absenceofOVA, withmurine amniotic
fluid, TGF-02, orPBS andnormal mouseserumcontrols,for72 h.Results
are themean of triplicate cultures (variability <15%) of onerepresenta-
tive experiment of more than three independent experiments. .120
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￿
Amniotic fluid and TGF-0 suppression ofILl-induced thymo-
cyte stimulation . Murine thymocytes were cultured, in the presence or
absence of sub-optimal levels ofPHA and 10 U/ml of rlIrl, with murine
amniotic fluid at 10% (vol/vol), TGF-#2 at 2 ng/ml, or PBS and normal
mouse serum controls at 10% (vol/vol) .
fibroblast cells to form colonies in soft agar (26), we tested
MAF in this assay . As shown in Fig . 3, TGF-# supportsAKR
2B colony formation at doses ranging between 0.2 and 30
ng/ml, while MAF stimulates increasing numbers ofAKR-
2B colonies at concentrations ranging from 1 through 20% .
TGF-0 inhibition ofthe growth oftheMv1Lu (CCIr64) mink
lung epithelial cell line is a sensitive assay for TGF-)3 (27,
28). Fig. 4 shows that 0.07 ng/ml ofTGF-ß2 inhibits Mv1Lu
thymidine incorporation by 50%, while 2 ng/ml inhibits by
>95% . This inhibition is duplicated byMAF, which demon-
strates a dose-dependent suppression ofMvILu thymidine up-
take with 50% inhibition at 0.15% MAF, and >95% inhi-
bition at 5% MAF (Fig. 4) .
To further define the nature of the suppressive activity in
MAF and its relation to TGF-ß, we evaluated the effect of
four different neutralizing antiTGF-# antibodies inmink lung
epithelial cell growth inhibition and in antigen-induced T
cell proliferation assays in the presence ofMAF, TGF-ß2, or
TGF-ßl . Two of the antiTGF-ß preparations are rabbit poly-
clonal antibodies. One rabbit antibody neutralizes mink lung
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Figure 3 .
￿
Amniotic fluid and TGF-# stimulation ofAKR-2B cell colony
formation in soft agar. AKR2B mouse embryonic fibroblast cells were
cultured in soft agar in the presence or absence of murine amniotic fluid
and TGF-#2 (or PBS and normal mouse serum controls), as described in
Materials and Methods .
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￿
Dose response of amniotic fluid and TGF-# suppression of
Mv1Lu growth . MvILumink lung epithelial cells (CCL64)werecultured,
as described in Materials and Methods, with the indicated concentrations
ofmurine amniotic fluid, TGF-#2, or PBS and normal mouse serum con-
trols. Results are the mean oftriplicate cultures (variability <10%) ofthree
independent experiments.
cell proliferative inhibition by both TGF-ß1 and TGF-ß2 .
This antisera, at 75-150 Fig/ml, completely neutralizes the
suppression ofantigen-inducedT cell proliferation caused by
10% MAF, as well as by 2 ng/ml of either TGF-01 orTGF-
#2 . This antibody also completely neutralizes the inhibition
of 11,1-dependent thymocyte proliferation caused by either
TGF-0 orMAFwhen added at the initiation of the prolifer-
ation assay (data not shown) . The second rabbit antibody
neutralizes only TGF-ß2 . As shown in Fig. 5, this antibody
abolishes mink lung epithelial cell proliferative inhibition
caused byMAF as well as TGF-ß2, but not byTGF-#1. Com-
plete neutralization of 1 ng/ml of TGF-ß2 is seen with 20
Fig/ml ofthis antibody, and the same amount totally abrogates
the inhibition caused by 5% MAF, while having no effect
on TGF-ß1 . The TGF-ß2-specific rabbit antibody also com-
pletely neutralizes, at 10-20 hg/ml, the immunosuppressive
effects caused by 10% MAF or 2 ng/ml ofTGF-ß2 in the
T cell proliferation assay, but does not significantly affect the
activity of TGF-ß1 (Fig . 6 A) .
Two additional neutralizing antiTGF-ß antibodies raised
Figure 5 .
￿
AntiTGF-#2-specific antibodies, but not antiTGF-#1, neu-
tralize amniotic fluid suppression of MvILu growth . Mv1Lu mink lung
epithelial cells were cultured with murine amniotic fluid at 5% (vol/vol),
or TGF-#1 or TGF-#2 at 1 ng/ml, in the presence or absence of20,ug/ml
ofrabbit anti TGF-#2-specific antibody, or 1:100 dilutions of turkey anti-
TGF-02-specific or antiTGF-#1-specific antibodies .
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in turkeys (24, 25) were also used to examine the TGF-0-like
activity in MAR The first is specific for TGF-#2 alone and
abolishes the inhibition of mink lung epithelial cell growth
caused by MAP as well as by TGF-/32, but not by TGF-/31
(Fig. 5). These anti-TGF-/32-specific antibodies completely
neutralize the suppression ofantigen-induced T cell prolifer-
ation by 2 ng/ml ofTGF-02 or 10% MAP at dilutions from
1:1,000 to 1:100, without affecting TGF-91 suppression (Fig.
6 B). The second turkey anti-TGF-a is specific for TGF-#1
and blocks mink lung epithelial cell growth inhibition by
TGF-a1, but not by TGF-/32 or by MAP (Fig. 5). At dilu-
tions of 1:1,000 to 1:100, this antiserum also abolishes TGF-
01 suppression in the T cell proliferation assay but does not
affect TGF-(32 or MAP immunosuppression (Fig. 6 C).
CS-1 Activity in Amniotic Fluid. MAP contains high levels
ofmacrophage (CSF-1) activity in bone marrow colony assays
in soft agar (Table 1). We have found that the CSF-1 activity
in MAF, equivalent to -1,000 CFU/ml of rCSF-1(Genzyme
Corp.), can be separated from the immunosuppressive activity
(measured by antigen-induced T cell proliferation) by size
exclusion chromatography. Heat treatment of MAP (>95°C
for 7 min) also eliminates CSF-1 activity, leaving the im-
munosuppressive activity unchanged (see Table 1). Purified
or recombinant CSF-1 does not suppress antigen-induced T
cell proliferation (Table 1), and neutralizing antibodies against
CSF-1 have no effect on MAP immunosuppression. Antisera
to AFP, albumin, IFN-ci, -0, and -.y, and TNF-ct also have
no effect on suppression by MAF or TGF-I0 when added at
the initiation of the T cell assay (data not shown). The im-
munosuppressive factor in MAP is stable to lyophilization
and acidification but sensitive to pronase.
Chromatographic Characterization ofMAF Immunosuppres-
sive and TG-0-likeActivities. Size exclusion chromatography
of MAP on Sephadex G-150 at neutral pH demonstrates (see
Fig. 7 A) that the immunosuppression is associated with frac-
tions eluting at -70 kD (containing mainly albumin and
AFP). The suppressive effect of these fractions is completely
neutralized by rabbit anti TGF-,132 but not by antisera to
TGF-(31. However, when MAP is chromatographed under
acidic conditions (pH 2.3) on BioGel P 100 (see Fig. 7 B),
the suppressive activity (assessed by inhibition ofboth antigen-
induced T cell proliferation and mink cell growth) elutes in
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￿
Anti-TGF-S2-specific antibodies, but not anti TGF-#l, neutralize amniotic fluid immunosuppression. Dose response ofanti-TGF-02 and
antiTGF-01 on the suppression of antigen-induced T cell proliferation by murine amniotic fluid at 10% (vol/vol), TGF-S2 and TGF-01 at 2 ng/ml.
(A) Rabbit anti-TGF-,Q2-specific antibody; (B) turkey antiTGF-,E2-specific antibody; (C) turkey antiTGF-J31-specific antibody.
a low molecular weight region in the same location as human
platelet-purified TGF-01 (pTGF-S), demonstrating the retarded
and anomalous elution reported for the mature 25-kD TGFLi6
molecule (38). The immunosuppressive and mink cell inhi-
bition activities eluted from BioGel acid chromatography, in
the low molecular weight region, are both completely neu-
tralized by the rabbit anti-TGF-)(32-specific antibody. Further,
when the 70-kD fractions obtained from chromatography
of MAP at neutral pH are subjected to chromatography at
acid pH, the anti-GF-a2-neutralizable, immunosuppressive
and mink cell inhibitory activities elute in the same location
as pTGF-a (data not shown). We have previously reported
(8) that the immunosuppressive activity in MAP can be par-
tially depleted after pretreatment with antibody to mouse
AFP. Pretreatment of native amniotic fluid with anti AFP
Table 1 .
￿
Dlferentiation of Immunosuppressive and CSF-1
Activities in Amniotic Fluid
' OVA-primed CBA mouse LN cells were cultured, in the presence or
absence ofOVA, with the indicated addition. Plates were incubated for
72 h, and [3HJTdR incorporation was measured as described in Mate-
rials and Methods.
t Bone marrow cells were obtained from DBA/2Ha mice and cultured
in soft agar in the presence of the indicated additions as detailed in Materials
and Methods. Colonies of >50 cells were counted at 7 and 14 d. The
experiements were repeated at least three times with equivalent results.
Addition
Percent suppression
of antigen-induced
T cell proliferation`
Bone marrow
soft agar
colonies/welt
Normal sera control
(10%) 0 0
Amniotic fluid
(10%) 92 29
Heat-treated amniotic
fluid (10%) 96 0
rCSF-1
(100 CFU/ml) 8 24
TGF-,B2 (2 ng/ml) 91 0
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Figure 7.
￿
Separation of the amniotic fluid TGF-02-like immunosup-
pressive activity by size exclusion chromatography. Immunosuppression
was evaluated by the inhibition of antigen-induced T cell proliferation.
TGF-02 activity was evaluated by the suppression of Mv1Lu cell growth
and the antiTGF-02-specific neutralization of suppression in both assays.
The suppressive fractions are indicated by the hatched bars. (A) Murine
amniotic fluid chromatographed on Sephadex G-150 with PBS at pH 7.1.
(B) Amniotic fluid chromatographed on BioGel P 100 with 1 M acetic
acid at pH 2.3.
coated glass beads removes suppressive activity (see Fig. 8),
whilebeadscoated with normal sera, anti-IgG, or anti-NMS
have minimal effect. Immunosuppressive activity is eluted from
the anti-AFP-coated beads by low pH (glycine, pH 3), and
this activity is fullyneutralized by antibodies to TGF-ß2 (Fig.
8). In addition, after chromatography of the acid extract on
BioGel P100 at pH 2.3, the immunosuppressive activity elutes
in a position similar to pTGF-ß (data not shown).
Northern Analysis ofTGF-ß mRNA Expression in Maternal
and Fetal Tissues. To determine the site(s) of synthesis of
the TGF-ß2-like immunosuppressive factor in MAF, we have
examined the expression of TGF-ß2 and TGF-ß1 mRNA in
various tissues during mouse gestation. Northern analysis of
mRNA prepared from 9.5-19-d fetuses, placental, and ma-
ternal tissues, was performed using a cDNA probe specific
for TGF-01 and another specific for TGF-ß2. We find that
TGF-ßl mRNA is expressed at low levels in many tissues
without significant gestational change and is not detected
in the pregnant uterus by the methods we used. Low levels
of TGF-ß2 mRNA were expressed in the fetus, placenta, and
the decidua with little variation during gestation. TGF-ß2
mRNA was present at low levels in the uterus on day 9.5
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￿
AntiAFP-coated glass bead removal of the amniotic fluid TGF-
ß2-like immunosuppressive activity. The suppressive activity is eluted from
the anti-AFPbeads exposed to MAFby glycine, pH 3, and is fully neutral-
ized solely by antiTGF-02-specific antibodies. Control beads coated with
normal serum, anti-mouse IgG, or anti-normal mouse serum have no
or minimal effect.
of gestation. However, strikingly high levels of TGF-132
mRNA were found in the day 12.5 uterus, reaching a max-
imum on day 15.5, as illustrated in Fig. 9. Between days 15.5
and 19 of gestation, there is a precipitous fall in the levels
of mRNA for TGF-ß2, which essentially disappears from
the uterus by day 19, immediately preceding birth (22). Non-
pregnant uterus contains little if any TGF-ß2 mRNA (data
not shown). The expression of TGF-ß2 mRNA in the preg-
nant uterus was seen coincidentally with CSF-1 mRNA, while
c-ms mRNA was essentially undetectable in the uterus with
significant levels appearing in the fetal placenta (data not
shown), as previously reported by Stanley and colleagues (39).
AFP mRNA was localized in the yolk sac, fetal liver, and
to a lesser extent, the fetal gut, in agreement with others
(40) (data not shown).
Figure 9.
￿
Northern analysis of TGF-02 and TGF-01 mRNA expres-
sion in fetal and maternal tissues during gestation. RNAs from day 15.5
of gestation fetus (F), placenta (P), decidua (D), and uterus (U), and the
PC-3 adenocarcinoma control (C) were prepared, subjected to electropho-
resis, and hybridized with a cDNA probe specific for TGF-02 and another
specific for TGF-ß1, as describedin Materials and Methods. Thepredomi-
nant pregnant uterine TGF-02 mRNA band is 3.5 kb with minor bands
of 5.0 and 4.1 kb. PC-3 shows a major TGF-ß2 band of 3.25 kb with
minor bands of 5.0 and 4.1 kb, and a major TGF-01 band of 2.3 kb. The
lower band in each lane is the mouse pIL7 rRNA probe, the internal hy-
bridization intensity loading control.
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The immunosuppressive activity in MAP is novel in that
it appears to be due to the presence of a specific TGF-ß2-like
factor. Although TGF-ß1 and g2 share many bioactivities,
such as inhibiting epithelial cell and keratinocyte prolifera-
tion and stimulating myocyte and adipocyte differentiation
(10, 11), some functional differences have been described . For
example, TGF-ß1 has been reported to be much more effec-
tive in inhibiting multipotential hematopoietic progenitor
cell responses to IL3 (41, 42) and in inhibiting vascular en-
dothelial cell proliferation (43), while TGF-ß2, but not TGF-
01, exhibits mesoderm-inducing activity in Xenopus embryos
(24) . Both TGF-01 andTGF-ß2 exhibit immunosuppression,
however, the immunosuppressive factor in MAP is structur-
ally and functionally related specifically to TGF-ß2 . From
our data, the concentration of TGF-ß2-like activity in native
MAP appears to be very high, equivalent to -40 ng/ml (1.6
nM) ofTGF-ß2 . We cannot exclude the possibility that some
TGF-ß1 activity is present inMAF, but the antibody inhibi-
tion studies suggest that there is<0.07 ng/ml, which would
yield a ratio of TGF-ß2 to TGF-ß1 activities in MAP of
>500:1. It is important to note that our data do not exclude
the possibility that the amniotic fluid immunosuppressive
factor is more closely related to another member of the
TGF-ß family, such as TGF-(33 (44, 45), than to TGF-ß2 .
TGF-ß3 has been shown to possess activities common to
TGF-/31 and TGF-(32 (46), and the TGF-,ß2-specific antisera
used could possibly crossreact with TGF-ß3, although they
do not react appreciably with TGF-ßl . It is unlikely that we
are detecting TGF-(33mRNA in the tissue studies, because
theTGF-ß2 specificcDNA probe used in the Northern anal-
ysis of gestational tissues was designed to eliminate the 3'
regions, which have greater sequence conservation in the
TGF-ß family, and our studies detect the transcript sizes pre-
viously identified asTGF-02 specific. Also, we used high strin-
gency hybridization conditions that would reduce crosshybridi-
zation . Nevertheless, further work, including amino acid
sequence analysis and gene cloning, is necessary to establish
whether the MAP TGF-ß2-like factor is : (a) identical to
TGF-ß2 ; (b) a modified form of TGF-ß2 ; (c) an already de-
scribed member of the TGF-ß family ; or (d) a unique new
family member.
The observation that at neutralpH the active suppressive
factor chromatographs in the 70-kD region peak suggested
that TGF-,l3 could possibly be complexed to a protein(s) in
amniotic fluid . This possibility is suggested by our data
showing that pretreatment ofMAP with beads coated with
antibodies to AFP removes suppressive activity, while beads
coated with other antibodies do not significantly affect ac-
tivity. Moreover, the immunosuppressive TGF-ß activity can
be eluted from the complexes and is neutralizable by anti-
TGF-ß2. Thus, the presence ofAFP in amniotic fluid presents
the potential for a unique carrier protein for TGF-ß2, and,
although additional and more definitive binding studies are
necessary, we speculate that theTGF-ß2 or a closely related
molecule in amniotic fluid can bind to AFP in a reversible,
noncovalent manner . AFP is synthesized largely in the fetal
liver and "back diffuses" across the placenta, where it could
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potentially play an important role in interacting with a po-
tent immunosuppressive TGF-ß-like agent at the placental
site. It is also possible that TGF-fl is carried into the maternal
circulation in an AFP complex, although we have not yet
determined whether the antiTGF-ß2 neutralizable factor is
present in pregnant serum. TGF-ß2 or a closely related factor
bound or released from APP could affect immune suppres-
sion locally at the level of the maternal-fetal interface, and
possibly in the mother, as well as the fetus, where immune
deficiencies have been described (1, 2) . Copurification, or "con-
tamination" ofAFP preparations with the TGF-ß2-like am-
niotic fluid factor, may account for the variable immunosup-
pression reported for AFP. For example, we have previously
observed (5) that methods ofisolatingAFP that involve chro-
matography with acidic buffers (which separates the TGF-
/32-like factor from AFP), or high concentrations of chao-
tropic/denaturing salts, produce nonsuppressive AFP prepa-
rations . Further, since AFP suppression in vitro is seen with
microgram/milliliter concentrations, while TGF-ß2 is im-
munosuppressive at picograrn/milliliter levels, even minute
quantities ofTGF-02 (one molecule per 106 o£AFP) could
account for suppression in apparently "pure" AFP prepara-
tions . It is possible that the suppressive specificities ofAFP
reported by van Oers et al . (9) are due to a particular struc-
ture that is capable ofbinding TGF-ß2 or the closely related
amniotic fluid factor.
The TGF-ß2-like MAP factor is active in immunosuppres-
sion andmink cell inhibition without acidification or apparent
proteolysis, which is usually necessary to activate the latent
form of TGF-(3 present in bone or secreted by platelets or
cultured cell lines . This suggests that theMAP immunosup-
pressive factor may represent a developmentally specific spe-
cies of TGF-ß that accumulates in a physiologically, active
form in amniotic fluid. It may also have a unique responsive-
ness to the hormones involved in pregnancy, since there is
a striking accumulation of TGF-ß2 mRNA in the uterus
during pregnancy . However, whether the TGF-ß2-like mol-
ecule in MAP is derived entirely 'or in part from synthesis
in the pregnant uterus remains to be proven . Recent studies
by Moses and colleagues (47, 48) have shownTGF-ß2mRNA
in the mid to late gestation mouse fetus and placenta using
a murine TGF-ß2 cDNA probe. Using our humanTGF-ß2
cDNA probe, hybridized under high stringency, we detected
high TGF-ß2 mRNA levels in the 12.5-15.5 d of gestation
uterus. In comparison, however, we did not detect significant
levels in the fetal placenta, yolk sac, amnion, or decidua. Dis-
crepancies between those reports and our data could be due
to differences in the probe used and/or the conditions of hy-
bridization. However, very recent data using the samecDNA
probe and hybridization conditions as those reports continue
to demonstrate the same localization depicted in Fig. 9 (data
not shown) . Further purification of the TGF-ß2-like factor
from MAP with the objective of biochemical characteriza-
tion (including sequencing) and cloning oftheTGF-ß2 gene
from pregnant uterus are currently in progress.
A studybyClark et al . (49) suggests that suppressor cells
from the murine decidua release a soluble 13-kD suppressorantigenically related to TGF-a. A recent report (50), which
appeared while this manuscriptwas in preparation, describes
a suppressive factor functionally and antigenically related to
TGF-a2 that is produced in decidual cell preparations. How-
ever, we detect only very small amounts of TGF-/32 mRNA
in carefully dissected decidual preparations. In comparison,
we find very high levels of TGF-,62 mRNA in the uterus
appearing after day 9.5 ofgestation with little or no TGF-(31
mRNA, despite the predominance of TGF-01 in most adult
tissues. One possible explanation is that the decidual prepa-
rations studied by Clark et al. (50) were contaminated with
uterine cells and/or TGF-02 protein produced in the maternal
uterine cells.
The uterine TGF-a2 mRNA reaches peak levels at about
day 15.5, followed by a rapid fall of mRNA levels, and by
day 19 of gestation, TGF-02 message is essentially undetect-
able (22). The dramatic fall of a potent immunosuppressive
factor as birth approaches raises interesting speculations con-
cerning the role ofthe TGF-02-like factor in the maintenance
of pregnancy and its relationship to the onset ofnormal birth,
as well as abortions and miscarriages. Additional data on the
complete time course and tissue distribution of TGF-/32 ex-
pression during gestation, using Northern analysis, as well
as in situ hybridization, is currently in progress.
Reports of additional immunomodulatory roles of TGF-/3
have appeared recently that expand the role of this factor in
immune regulation. TGF-(3 has been identified as a cofactor
in stimulating IgA productionin B cells (51) and as an inhib-
itor of the generation of cytotoxic T cells directed against
virally infected cells (52). Immunogenic tumors expressing
TGF-/3 (53), either as a result of transfection of the TGF-0
gene or spontaneous production, and human glioblastomas
that produce TGF-02 (54), havebeen shown to suppress and
evade host immune responses. These studies suggest that
TGF-/3, produced either by the tumor or by host cells
infiltrating the tumor, may play an important role in regulating
tumor rejection. Recent studies showing that TGF-R sup-
presses NK cell activity (19) and the production oflymphokine-
activated killer cells (55, 56) are consistentwith this hypothesis.
TGF-/3 treatment has been reported to promote the accep-
tance of rat to mouse pancreatic islet cell xenografts when
given with anti-IFN-y (57). This is consistent with our work
(7) demonstrating that amniotic fluid administered in-
traperitoneally prevents skin graft rejection across minor
histocompatibility barriers in mice. In these studies, MAF,
containing the TGF-02-like factor, was given in large amounts
without apparent toxicity and resulted in permanent engraft-
ment that in most animals persisted after cessation of the treat-
ment. These studies provide an impetus to further explore
the use of the TGF-02-like factor (as well as rTGF-f3) in trans-
plantation, as well as in GVHD and autoimmunity.
The precise mechanism(s) by which TGF-ft suppresses im-
mune responses is uncertain. Previous studies have reported
various effects on the growth, cell cycling, and function of
T cells (and possibly I1r2Rs) (17, 56, 58-60), and of B cells
(61, 62). Modulations of cell adhesion receptors such as LFA1
(63), and of MHC class II expression (62, 64, 65), have also
been reported. With regard to MHC expression, prior reports
(66, 67) have suggested an inhibition of macrophage cell sur-
face la by AFP, an observation consistent with our previous
finding (68) that MAF and AFP suppress antigen-induced
T cell proliferation at the level of the APC. Whether this
effect is related to thebinding of TGF-0 to AFP, as discussed
above, is unknown, but deserves further exploration. It will
be of particular interest to determine whether the TGF-J32-
like factor is involved in the deficiencies in MHC antigen ex-
pression on fetal and placental tissues that have been reported
and postulated to be important in fetal survival (1, 2). We
have recently shown that TGF-0 and the amniotic fluidTGF-
02-like factor modulate macrophage and B cell MHC class
II gene expression and surface la induced by certain cytokines
(23). However, the effects of TGF-(3 and the TGF-/32-like
amniotic fluid factor on la expression are complex and de-
pend on the cell type, state of differentiation, and the nature
of la-inducing cytokines present (23).
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